Skip to main content
Caplight Logo









Pheno Therapeutics

Pheno Therapeutics

Private
EdinburghHealthcare & Life Scienceshttps://phenotherapeutics.com

Last Round

Series A

Feb 18, 2020

Total Funding Raised

$6.5M

Company Overview

Pheno Therapeutics is a biotechnology company that develops remyelinating therapies designed to halt disability progression in demyelinating diseases such as multiple sclerosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Application

Keywords

remyelination therapymultiple sclerosissmall molecule therapyGPR17 antagonistclinical-stage biotechdrug discovery platformphenotypic screeningAI drug discoveryneurodegenerative diseasefirst-in-class drugpharma licensinghigh-content imaging

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pheno Therapeutics Comparables

Compare Pheno Therapeutics with similar companies based on industry and business-model similarity.

Pheno Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rewind Therapeutics
86%
Convelo Therapeutics
86%
Myrobalan Therapeutics
85%

Pheno Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 18, 2020

Key People

Founding team and executive leadership

Fraser Murray

Chief Executive Officer

Executive Team

Pheno Therapeutics Investors

Notable investors and investment history

Pheno Therapeutics investors
InvestorRounds
Advent Life SciencesSeries A
LifeArcSeries A
Scottish Investment Bank (Scottish Enterprise)Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors increased 68% MoM, reaching 2.2K.

  • Mar 1, 2026

    Monthly visitors grew 32% MoM, reaching 2.4K.

Pheno Therapeutics Filings

Explore SEC and related filing metadata, where available.

Pheno Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Pheno Therapeutics's valuation, stock price, and market status.

Is Pheno Therapeutics a public or private company?

Pheno Therapeutics is a private company.

What is the current stock price of Pheno Therapeutics?

Pheno Therapeutics is a private company, so its shares have no public market price. Caplight tracks Pheno Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Pheno Therapeutics worth (valuation)?

Valuation information for Pheno Therapeutics is not publicly available.

Can I buy Pheno Therapeutics stock?

Pheno Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Pheno Therapeutics's last funding round?

Pheno Therapeutics's most recent funding round was Series A on February 18, 2020.

Who are the main investors in Pheno Therapeutics?

Key investors in Pheno Therapeutics include Advent Life Sciences, LifeArc, Scottish Investment Bank (Scottish Enterprise).

Will Pheno Therapeutics IPO soon?

No public IPO plans have been announced for Pheno Therapeutics.

How can I track Pheno Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades in Pheno Therapeutics's shares on secondary markets.

Firmographic Details

HeadquartersEdinburgh
Employee Range7
Year Founded2019
Last FundingFeb 18, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?